key: cord-0040421-6jti6jxt
authors: Wenzel, Richard P.
title: Acute Bronchitis and Tracheitis
date: 2012-05-08
journal: Goldman's Cecil Medicine
DOI: 10.1016/b978-1-4377-1604-7.00096-8
sha: 3d68b348af2ae830d43cef05da91a9a28dcba5d7
doc_id: 40421
cord_uid: 6jti6jxt

nan

observed in the winter and fall than in the summer and spring. In the United States, acute bronchitis and tracheitis is the ninth most common illness in outpatients as reported by physicians.

The disorder is thought to be viral in origin almost all the time. However, viruses have been isolated in only 8 to 37% of patients. Thus, the true causes of the illness are unknown in most cases. Nevertheless, at least 70% of patients with acute bronchitis and tracheitis in the United States receive antibacterial antibiotics after visiting a physician. Importantly, although the same bacteria that are commonly implicated in community-acquired pneumonia are also isolated from the sputum in half the patients, their role in the pathobiology of acute bronchitis and tracheitis or its attendant symptoms is unclear, and bronchial biopsies have not shown bacterial invasion.

Infections of the epithelium of the bronchi and trachea are thought to incite an inflammatory response. Pathologically, there is an accompanying microscopic thickening of bronchial and tracheal mucosa corresponding to the inflamed areas. Such pathologic findings are also consistent with the occasional case report of upper airway inflammation confined to the bronchi and trachea detected by 18 F-labeled fluorodeoxyglucose positron emission tomography (FDG-PET).

In human experimental rhinovirus infections (Chapter 369), virus was detected in all subjects in induced sputum samples and also in approximately one third of bronchial biopsy specimens, almost one fourth of bronchoalveolar lavage samples, and more than one third of biopsy and brushing samples. Such data indicating viral infection of the lower airways may help explain the relationship observed between rhinovirus infection and exacerbations of asthma (Chapter 87). Furthermore, pathologic islands of inflammation have been found in the trachea with rhinovirus infection, thus supporting the idea of a patchy distribution. The viruses implicated in acute bronchitis and tracheitis include influenza A and B (Chapter 372), parainfluenza (Chapter 371), respiratory syncytial virus (Chapter 370), coronavirus (Chapter 374), adenovirus (Chapter 373), and rhinoviruses (Chapter 369), usually in this order from the most to the least common. However, a recent French study of influenza-vaccinated adults found a viral cause in 37% of 164 cases of acute bronchitis, 21% of which were rhinovirus. Thus, at least three variables can influence the yield of specific pathogens: the presence of epidemics, the

The term acute bronchitis and tracheitis defines a self-limited (1 to 3 weeks) inflammation of the large airways of the lung that extends to the tertiary bronchi ( Fig. 96-1 ). In patients with a primary symptom of cough (Chapter 83), the diagnosis is made if there is no clinical or radiologic evidence of pneumonia. At the bedside, the absence of criteria for systemic inflammatory response syndrome (SIRS) (Chapter 108) suggests bronchitis and tracheitis and makes a diagnosis of pneumonia (Chapter 97) unlikely. The SIRS criteria are met if the patient has more than two of the following: temperature lower than 36° C or higher than 38° C, pulse greater than 90 beats/minute, respiratory rate higher than 20 breaths/minute, or white blood cell count less than 4000 cells/mm 3 or higher than 12,000 cells/mm 3 or with greater than 10% bands.

The definition of acute bronchitis and tracheitis also seeks to differentiate the illness from acute inflammation of the small airways (bronchiolitis), even though the accompanying symptoms with the former may include sputum production, wheezing, and shortness of breath. Among patients with primarily small airways disease, some might be expected to have prominently decreased breath sounds in the areas involved. Acute bronchitis and tracheitis is also different from bronchiectasis (Chapter 90), which is associated with permanent dilation of bronchi and a chronic cough. Furthermore, a diagnosis of chronic bronchitis (Chapter 88) is reserved for patients who have prolonged cough and sputum production: at least 3 months of the year for 2 consecutive years.

Occurring at a rate of 44 per 1000 adults per year, acute bronchitis and tracheitis affects approximately 5% of adults annually. A higher incidence is season of the year, and the population's influenza vaccination status. More recently, human metapneumovirus (Chapter 369) has been identified as an etiologic agent.

Up to 10% of cases of acute bronchitis and tracheitis may be due to "atypical" bacteria: Bordetella pertussis (Chapter 321), Chlamydophila (Chlamydia) pneumoniae (Chapter 325), and Mycoplasma pneumoniae (Chapter 326). Severe bronchiolitis has also been reported with M. pneumoniae, even though this pathogen is usually associated with either pneumonia or acute bronchitis and tracheitis in adults. In children, bronchiolitis has been associated with respiratory syncytial virus, influenza virus, parainfluenza virus, and metapneumovirus (Chapter 369). Thus, there are probably wide variations in the anatomic distribution of all pathogens causing acute bronchitis and tracheitis, extending from the nasal mucosa to the bronchiolar epithelium.

The cardinal clinical symptom is cough (Chapter 83) of recent onset. Because most upper respiratory infections resolve within 1 week, a more extended period of cough is useful for considering the diagnosis of acute bronchitis. Patients usually seek care from their physician after 4 to 7 days of coughing that is not resolving. With acute bronchitis, there is often a continued cough and sometimes a worsened cough that lasts an initial 1 to 3 weeks. Associated symptoms vary and include sputum production, fever, malaise, wheezing, and dyspnea. Adults with pertussis may exhibit paroxysms of coughing, whooping, or vomiting, although less commonly than seen in children with this infection.

Acutely ill patients may not be able to distinguish their early symptoms from those accompanying very mild upper respiratory infections. However, with acute bronchitis and tracheitis, a protracted phase of coughing persists beyond 1 to 5 days, during which time pulmonary function tests may become abnormal. A substantial proportion of patients will have significant declines in forced expiratory volume in the first second (FEV 1 ) (Chapter 85).

Rapid diagnostic tests exist for most viruses linked to acute bronchitis and tracheitis. However, their value lies in identifying a virus for which there is therapy or avoiding antibacterial antibiotics if any virus is identified. Not all rapid tests are widely available, and they are expensive and rarely cost-effective in an outpatient setting.

When "atypical" bacteria are identified by culture or serology, patients tend to be seen later in the course of their illness than patients with viral causes and more often have wheezing. In some studies, 12 to 32% of patients with coughing that persists for longer than 1 week had pertussis. In other studies, however, pertussis has been confirmed in only 1% of such patients.

Polymerase chain reaction (PCR) testing of nasopharyngeal swabs or aspirates is the easiest and most sensitive way to diagnose infections by B. pertussis, M. pneumoniae, and C. pneumoniae; most experts recommend calcium alginate swabs for pertussis because cotton inhibits growth. Dacron swabs with aluminum handles are preferred for specimens used to diagnose Chlamydophila because cotton, calcium alginate, and the wooden shaft can all inhibit growth of the organism. Cultures for M. pneumoniae are slow and insensitive. In general, testing for atypical organisms should not be done because of the cost of PCR and both the insensitivity and slowness of cultures. However, if the clinician suspects an outbreak in the community or the likelihood of pertussis, rapid testing with PCR may be quite beneficial.

Coughing usually lasts 10 to 14 days, during which time the illness causes significant transient decrements in vitality and social functioning. Limited data on short-and long-term outcomes show that up to 20% of patients have persistent or recurrent symptoms for a month. Antibiotics may reduce symptoms by a fraction of a day, but side effects, the emergence of antibiotic resistance, and cost must be weighed against their modest benefits. The mean duration of an office visit for adults in the United States with upper respiratory tract infections is 14.2 minutes when patients are prescribed antibiotics versus 15.2 minutes without prescription of antibiotics, but antibiotic use is not an independent predictor of visit length. Future widespread use of rapid diagnostic tests for specific bacterial and viral pathogens will be useful in targeting effective therapies.

In a meta-analysis of nine randomized trials of antibacterial antibiotics for acute bronchitis, patients receiving antibiotics were significantly less likely to have a cough, but their 0.58 fewer days with cough, 0.52 fewer days of productive cough, and 0.58 fewer days of feeling ill were not statistically significant. 1 A large clinical trial in a population with a high prevalence of human immunodeficiency virus infection found that amoxicillin for 7 days was no better than placebo. 2 These results are not surprising because, at most, about 50% of cases are probably caused by bacterial pathogens. Nevertheless, antibiotics are used in 50 to 85% of cases worldwide.

Antibiotics may be used in patients with known atypical pathogens, but even then their effect on outcomes is not clear except to limit the spread of pertussis, especially during a defined outbreak. In adults suspected of having pertussis, erythromycin, 500 mg four times a day for 14 days, is thought to be most effective. However, many patients cannot tolerate erythromycin, and either doxycycline, 100 mg every 12 hours, or a newer macrolide such as TREATMENT azithromycin, 500 mg on day 1 and 250 mg/day thereafter, is effective. The latter two drugs are also active against C. pneumoniae and M. pneumoniae, although the optimal duration of therapy for acute bronchitis is unknown. A useful range is 5 to 14 days.

During influenza season, anti-influenza agents may be useful in decreasing symptoms by approximately 1 day and may lead to a 0.5-day earlier return to normal activity in patients with influenza. The first-generation drugs amantadine and rimantadine are ineffective against H3N2 influenza A viruses and are not recommended. Second-generation drugs such as zanamivir (two inhalations of 5 mg each, twice a day) or oseltamivir (75 mg twice a day) can be given for 5 days. Up to 20% of patients given oseltamivir will have nausea or vomiting.

Antihistamines and over-the-counter antitussives and expectorants have no apparent value. Subsets of patients with bronchial hyperresponsiveness may benefit from β-agonists, but no data support the use of inhaled steroids. Mucolytic agents may be of small benefit. 3 In experimental rhinovirus colds, nonsteroidal drugs, alone or in combination with antihistamines, reduce the severity of symptoms, including cough. However, the widespread use of either type of drug alone or as a combination in naturally occurring, community-acquired bronchitis and tracheitis has not been evaluated. In patients with acute bronchitis, a meta-analysis of four placebo-controlled clinical trials suggested that Pelargonium sidoides (a herbaceous perennial widely used in Europe) reduced bronchitis symptom scores by day 7. 4

Antibiotics for acute bronchitis

Placebo found equivalent to amoxicillin for treatment of acute bronchitis in Nairobi, Kenya: a triple-blind randomized, equivalence trial

Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease

Pelargonium sidoides for acute bronchitis: a systematic review and meta-analysis

SUGGESTED READINGS

Airway mucus function and dysfunction

Antibiotics in acute exacerbations of chronic bronchitis